Trials / Conditions / Giant Cell Glioblastoma

Giant Cell Glioblastoma

22 registered clinical trials studyying Giant Cell Glioblastoma.

Status	Trial	Sponsor	Phase
Suspended	Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma NCT06806228	Petrov, Andrey	Phase 1
Withdrawn	HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma NCT04482933	Pediatric Brain Tumor Consortium	Phase 2
Withdrawn	CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type NCT05218408	Celularity Incorporated	Phase 1 / Phase 2
Terminated	Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM NCT04489420	Celularity Incorporated	Phase 1
Withdrawn	Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Re NCT03014804	Jonsson Comprehensive Cancer Center	Phase 2
Completed	Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma NCT03027388	National Cancer Institute (NCI)	Phase 2
Completed	Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma NCT02709226	National Cancer Institute (NCI)	Phase 1
Completed	DC Migration Study for Newly-Diagnosed GBM NCT02366728	Mustafa Khasraw, MBChB, MD, FRCP, FRACP	Phase 2
Completed	Vaccine Therapy in Treating Patients With Recurrent Glioblastoma NCT03360708	Mayo Clinic	EARLY_Phase 1
Completed	Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma NCT01957956	Mayo Clinic	EARLY_Phase 1
Completed	p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors NCT01975116	Pediatric Brain Tumor Consortium	Phase 1
Terminated	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors NCT01836549	Pediatric Brain Tumor Consortium	Phase 2
Completed	Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma NCT01250470	Roswell Park Cancer Institute	Phase 1
Completed	Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors NCT01609790	National Cancer Institute (NCI)	Phase 2
Completed	Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Ponti NCT01514201	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma NCT01498328	Celldex Therapeutics	Phase 2
Completed	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma NCT01480479	Celldex Therapeutics	Phase 3
Completed	Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions NCT01082926	City of Hope Medical Center	Phase 1
Completed	Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosa NCT01149850	Jonsson Comprehensive Cancer Center	Phase 2
Completed	Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Tre NCT00960492	Exelixis	Phase 1
Withdrawn	Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM NCT00943462	Centre hospitalier de l'Université de Montréal (CHUM)	—
Terminated	Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma NCT01095094	Case Comprehensive Cancer Center	Phase 2